New brain tumor scan could sharpen treatment decisions

NCT ID NCT06667726

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial at Mayo Clinic is testing whether adding an amino acid PET/CT scan (using a radioactive tracer called FDOPA) to standard imaging can improve clinical management for people with brain tumors. The study will enroll 47 adults with brain tumors to see if the extra scan changes treatment plans in over half of cases. Researchers will also track side effects and whether the scan finds tumors outside standard MRI areas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fluorodopa F 18 (18F-DOPA)
What this could lead to
If successful, this imaging technique could help doctors better plan treatment for brain tumors, such as surgery or radiation, and more accurately distinguish tumor growth from treatment side effects.
What could go wrong
This is a small, early-phase trial with only 47 participants, so results may not apply to everyone. The scan involves a radioactive tracer, though doses are very low.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.